Tech Company Financing Transactions
Disc Medicine Funding Round
Disc Medicine, operating out of Cambridge, scored investment capital from OrbiMed, 5AM Ventures and Access Industries.
Transaction Overview
Company Name
Announced On
9/2/2021 11:34:39 PM
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to develop its hematology pipeline of therapeutic candidates.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 Cambridgepark Dr. 103
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Undisclosed
Website
Email Address
Overview
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis). Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is advancing first-in-class therapies to transform the treatment of hematologic disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Quisel
Chief Financial Officer
Joanne Bryce
Chief Medical Officer
William Savage
Vice President
Srikanth Venkatraman
Vice President
Hua Yang
VP - Bus. Development
Jonathan Yu
VP - Regulatory Affairs
Sarah Tuller
Browse more venture capital transactions:
Prev: 9/2/2021: Asher Bio venture capital transaction
Next: 9/2/2021: Tabular venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs